Takeda sheds off-patent drugs to focus on innovation

17-04-2017

Takeda will sell a number of its off-patent drugs, used for treatment of diabetes, hypertension and peptic ulcers, to Teva Takeda Yakuhin for ¥28.5 billion ($35.7 billion).


Takeda, patent, Teva Takeda Yakuhin, diabetes, hypertension, ulcers, market exclusivity, innovation

LSIPR